QNTM Quantum Biopharma Ltd.
Debt Financing ·
A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures.
Quantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision.
Quantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.8 million | $6.1 million |
| Cash from operations | -$8.2 million | -$6.9 million |
| Cash and equivalents | $1.9 million | $6.0 million |
| Short-term investments | $459,080 | $1.2 million |
Our latest story on this, dated Sep 2, 2026: "Quantum BioPharma applies to delist Class B shares from the CSE". The story links the filing or release it is based on. Read the story.
Quantum Biopharma Ltd. trades under the ticker QNTM on NASDAQ.
Quantum Biopharma Ltd. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0K91; LS:A2P8F1; LSX:A2P8F1.
The SEC Central Index Key (CIK) for Quantum Biopharma Ltd. is 1771885. Its filings are on SEC EDGAR.
72 shares as of 2023-12-31, per the cover page of its 20-F filed 2025-03-28.
Our directory records Quantum Biopharma Ltd. under Canada.
Our directory classifies Quantum Biopharma Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Quantum Biopharma Ltd. is CA74764Y2050.
aibio.space lists Quantum Biopharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A6.
$2.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$2.4 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Our latest story on Quantum Biopharma, dated Sep 17, 2026: "Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants". A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. Source.
Our latest debt story, dated Sep 17, 2026: "Quantum BioPharma closes fourth debenture tranche of $100,000, cancels director warrants". A news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures. Source.
From our story of Mar 27, 2026: The release's headline also cites a "No Going Concern" status. Source.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio